Zheng, Y., Danilenko, D.M., Valdez, P., Kasman, I., Eastham-Anderson, J., Wu, J. and Ouyang, W. (2007) Interleukin-22, a t(h)17 cytokine, mediates il-23-induced dermal inflammation and acanthosis. Nature, 445, 648-651. doi:10.1038/nature05505

has been cited by the following article:

• TITLE: Remission of arthritis but persistent cutaneous lesions following tocilizumab treatment in a RA-patient suffering from concomitant psoriasis

  AUTHORS: Wolfgang Hartung, Boris Ehrenstein, Rotraud Wallisch, Martin Fleck

  KEYWORDS: Tocilizumab; Rheumatoid Arthritis; Psoriasis; Treatment

  JOURNAL NAME: Case Reports in Clinical Medicine, Vol.2 No.1, March 25, 2013

  ABSTRACT: Modulation of the interleukin-6 pathway with tocilizumab has been demonstrated to be highly effective in substantial numbers of patients suffering from rheumatoid arthritis (RA), and juvenile idiopathic arthritis. A pivotal role of the IL-6 pathway has been also established in other autoimmune conditions including psoriasis and psoriatic arthritis, becoming attractive targets for therapeutic IL-6 inhibition. Here, we describe the first case of tocilizumab treatment in a RA-patient suffering from concomitant severe psoriasis, who achieved remission of RA, whereas no improvement of psoriatic lesions could be observed.